Willie Nelson, who turned 80 on April 30, once sang a song about an alarm clock that rang two hours late, a garbage man who spilled all the trash on the sidewalk, hinges that were falling off the gate, spilling his coffee, and having his wife leave him -- all on the same day. Some health-care stocks might need their own country songs after the past few days. Here are three of the most horrendous health-care stocks over the last week.
Greenway doesn't report its quarterly results until next week, but the electronic health record systems vendor decided to let the cat out of the bag early. The company projects revenue for the fiscal year ending June 30 of $132 million to $134 million. That range is lower than the $145 million to $150 million Greenway expected less than three months ago.
Earnings will also probably be lower. Greenway's earlier guidance called for GAAP earnings of $0.10 to $0.17 per share. The company now expects a loss of $0.11 to $0.13 per share.
Greenway CEO Tee Green says the reason behind the weaker numbers is a faster-than-expected move by customers to the company's software-as-a-service model. Under the previous approach, Greenway booked higher revenue up front. While this shift was planned, the transition is going faster than executives thought it would.
The sky didn't fall, but it might have seemed like it this week for shareholders of Five Star Quality (NYSE: FVE ) . The stock dropped 21% after the operator of long-term-care facilities reported quarterly earnings.
Five Star announced first-quarter earnings of $1.9 million, or $0.04 per share. That reflected improvement from the $369,000, or $0.01 per share, reported in the same quarter of 2012. However, the earnings fell short of the $0.07 per share analysts expected.
The chief problem for Five Star came from a lower occupancy rate. CEO Bruce Mackey expressed disappointment in this trend. However, Mackey and investors probably aren't too disappointed with the stock over the past year. Shares are up 44% since May 2012 even with this recent big drop.
Astex Pharmaceuticals (NASDAQ: ASTX ) shares fell nearly 14% this week. The company reported financial results for the first quarter that the market initially welcomed, with shares up 1% in after-hours trading on Monday. That welcome wore out quickly, though.
The biotech reported first-quarter earnings of $488,000, or $0.01 per share, down from $4.2 million, or $0.05 per share, in the same period from last year. Revenue for the quarter totaled $22,1 million, only slightly higher than the $22 million reported for first quarter 2012.
Astex hopes to eventually transition from dependence on bone marrow disease drug Dacogen for its viability. The company has several drugs in mid-stage clinical studies, including experimental candidate SGI-110, which targets treatment of myelodysplastic syndromes and acute myeloid leukemia.
Does Willie Nelson need to write a depressing country song for all three of these stocks? Maybe not.
I think Greenway could see blue skies ahead. The company's woes seem to be largely transitory in nature. The market for health technology should remain strong, and I think Greenway's shift to the software-as-a-service revenue model will be good over the long run.
However, I think there are better plays in this health technology sector. Like most investors, finding the best stocks out there is always on my mind.
What macro trend was Warren Buffett referring to when he said "this is the tapeworm that's eating at American competitiveness"? Find out in our free report: "What's Really Eating at America's Competitiveness." You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.